Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announced today that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides […]
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficile infection (CDI) […]
Living in and on our bodies are trillions of microbial cells belonging to thousands of bacterial species – our microbiome. These microbes play key roles in human health, but little is known about their evolution. […]
Fecal transplant changes the gut microbiome, turning cancer immunotherapy non-responders into responders. Video Credits: UNIVERSITY OF PITTSBURGH Researchers at UPMC Hillman Cancer Center and the National Cancer Institute (NCI) demonstrate that changing the gut […]
In recent years, the understanding of how the microbiome and human health are linked has expanded considerably. We believe the rise in this understanding and the growing interest towards our microbiome research-focused Health for Life […]
Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced positive interim results from the K031 non-IND controlled clinical study evaluating outpatients with mild to moderate COVID-19 disease. Patients in this non-IND clinical study were randomized within 48 […]
People infected with COVID-19 experience a wide range of symptoms and severities, the most commonly reported including high fevers and respiratory problems. However, autopsy and other studies have also revealed that the infection can affect […]
ExeGi Pharma LLC, a U.S.-based company focused on developing and commercializing products targeting the human microbiome, including live biotherapeutic products (LBPs), announced today the results of a 70-patient clinical trial evaluating a new biologic drug […]
Seres Therapeutics, Inc. (Nasdaq: MCRB) today reported positive topline results from the pivotal Phase 3 ECOSPOR III study evaluating its investigational oral microbiome therapeutic SER-109 for recurrent C. difficile infection (CDI). The study showed that […]
At the beginning of 2020, I said to the Seventure team, that this would be the ‘Year of the Microbiome’.I still believe this will be true even in a COVID-19 world when our lives have […]
The adage “all things in moderation” applies not to just to food and drink, but also to the legions of bacteria inside our guts helping us digest that food and drink. It turns out the […]